ArticleEnvironmental science and pollution research international2015
Virulency of novel nanolarvicide from Trichoderma atroviride against Aedes aegypti (Linn.): a CLSM analysis.
Article in Environmental science and pollution research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Larvicidal activity of Trichoderma atroviride (Hypocreales: Hypocreaceae) against Aedes albopictus (Diptera: Culicidae).Journal of medical entomology · 2025Article
- In vitro evaluation of the pathogenicity of fungi isolated from the Urabá region (Antioquia, Colombia) against Aedes aegypti larvaeBiomedica : revista del Instituto Nacional de Salud · 2024Article
- The Potential ofNanomaterials (Basel, Switzerland) · 2023Review
- Green Nano-Biotechnology: A New Sustainable Paradigm to Control Dengue Infection.Bioinorganic chemistry and applications · 2022Review
- Innovative Preventive and Resilience Approaches AgainstOman medical journal · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aedes aegypti is the vector for transmitting dengue, chikungunya, and yellow fever. These diseases' transmission has increased predominantly in urban and semi-urban areas as a major public health concern. In present investigation, Trichoderma atroviride culture filtrates were used for the synthesis of silver nanoparticle. Moreover, T. atroviride is a free-living and rapidly growing fungi common in soil and root ecosystem. This fungi is an exceptionally good model for biocontrol and more significant as a bioagent. T. atroviride was grown in malt extract. T. atroviride culture filtrates were exposed to silver nitrates solution for 24 h at 25 °C for the synthesis of silver nanoparticles (AgNPs). These AgNPs were characterized to find their unique properties with UV-visible spectrophotometer and transmission electron microscope (TEM) analysis. The T. atroviride culture filtrates have formed hexagonal (diamond shape) AgNPs with the range of size of 14.01-21.02 nm. These AgNPs have shown significant efficacies against first, second, third, and fourth instar larvae of A. aegypti. The LC90 and LC99 values for the first instar were 1 and 3 ppm, second instar 2 and 3.18 ppm, third instar 3.12 and 4.12 ppm, and fourth instar 6.30 and 6.59 ppm, respectively, after an exposure of 7 h. The confocal laser scanning microscopy (CLSM) studies were verdict that these AgNPs embedded in the cuticle of larvae and cause instant lethality in 7 h. Present investigations have demonstrated that the AgNPs of T. atroviride culture filtrates synthesized can be used for larvae control of A. aegypti. T. atroviride is synthesized to silver nanoparticles to be a promising new candidate for application in mosquito control. We therefore suggested that the ability of T. atroviride culture filtrates in synthesis can also be explored for synthesizing silver nanoparticles for commercial exploitation.
Indexed as
Identifiers
25907629What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.